Based on data from drug‐adapted cells in culture, the efficacy of co‐drugging these cells with kinase and BET bromodomain inhibitors and analysis of gene expression profiles in human melanoma biopsies, we propose a speculative model for the adaptive resistance to RAF/MEK inhibition characterized in this paper. The gene discussed is MAP2K7; the disease is melanoma.